In a cluster-randomized , crossover trial with strategies rotated in @-month periods , we tested the noninferiority of the beta-lactam strategy to the beta-lactam-macrolide and fluoroquinolone strategies with respect to @-day mortality , in an intention-to-treat analysis , using a noninferiority margin of @ percentage points and a two-sided @ % confidence interval .